Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT05453279 Not yet recruiting - COVID-19 Clinical Trials

A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects

Start date: September 1, 2022
Phase: Phase 1
Study type: Interventional

This study will be a single center, Phase I, randomized, double-blind, placebo controlled, single and multiple ascending dose (SAD/MAD) study evaluating the safety, tolerability, and PK of Delcetravir after administration via oral inhalation in healthy subjects.

NCT ID: NCT05445479 Not yet recruiting - COVID-19 Clinical Trials

Retrospective Study for Identificatiopn of a Link Between Doxycycline and COVID-19 Treatment

DOXY-COVID
Start date: September 2022
Phase:
Study type: Observational

A new coronavirus, the third documented animal-to-human passage, emerged in Wuhan , China in the last quarter of 2019. Acne patients on doxycycline escaped seasonal viruses, showing the interest of this antibiotic as a possible treatment against COVID-19. The antiviral action of tetracyclines can be explained by different mechanisms. First of all, tetracyclines are modulators of innate immunity by decreasing NF-B expression, inhibiting inflammatory cytokines such as TNF-α, IL-1β and IL-6, inflammatory granulomas and free radical release . This action is obtained at doses lower than those necessary to obtain an antibiotic effect. Another possible action of tetracyclines is their ability to chelate zinc from matrix metalloproteinases (MMPS). The coronavirus family is known to bind to host MMPs, particularly for viral survival. Their chelating activity may help inhibit SARS-CoV-2 infection by limiting its ability to replicate in the host. Finally, tetracyclines could have a direct action by inhibiting the replication of single-stranded RNA virus, such as the SARS-CoV-2 coronavirus.We therefore propose a larger comparative study using data from the French National Health Data System.

NCT ID: NCT05433272 Not yet recruiting - COVID-19 Clinical Trials

Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), Inactivated

Start date: August 10, 2023
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, active-controlled phase Ⅲ clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of one booster dose of trivalent COVID-19 vaccine (vero cell), inactivated, prototype strain, delta strain and omicron strain in healthy people aged 3 years old and above and have completed two or three doses of CoronaVac® in Colombia.

NCT ID: NCT05422963 Not yet recruiting - COVID-19 Clinical Trials

Multiple-Center Retrospective Study of Severe and Critical COVID-19 in Shanghai

Start date: June 10, 2022
Phase:
Study type: Observational

This study is to clarify the clinical characteristics of severe and critical COVID-19 from March 1st ,2022 to June 9th, 2022 in Shanghai and to explore the relationship between the characteristics and prognosis in these patients.

NCT ID: NCT05421247 Not yet recruiting - COVID-19 Clinical Trials

A Study on Children With COVID-19 Admitted at Assiut University Children Hospital

Start date: September 2022
Phase:
Study type: Observational

The aim of study is to: 1-describe demographic and clinical data of children infected with COVID-19 admitted at isolation unit of Assiut university children hospital 2- assess the risk factors responsible for complications of COVID-19 in children 3-assess the outcome of COVID-19 in children admitted at AUCH.

NCT ID: NCT05421221 Not yet recruiting - COVID-19 Clinical Trials

Olfactory Training in COVID-19 Associated Loss of Smell

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

Olfactory dysfunction (OD) like hyposmia or anosmia has been realized as a common symptom or even cardinal sign of the disease and can be persisting after recovering. There are two different hypotheses on the pathogenesis of OD in past COVID-19: The central hypothesis, which speculates on neurotrophic abilities on olfactory receptors in the neuroepithelium, and the peripheral hypothesis, which speculates on damage of the sensory olfactory epithelium. Potential treatment strategies aim for the unique neural plasticity of the olfactory system and its potential for recovery. Clinical studies and case reports have shown a promising effect of olfactory training (OT) by frequent sniffing and/or exposure to odors 2-4 times a day for several weeks. The main objective of the study is to assess the effects of olfactory training in patients with COVID-19 related OD on: 1. objective olfactory testing with the Sniffin' sticks test (identification and discrimination) (primary endpoint), 2. subjective OD and its impact on the daily life (key secondary endpoint), 3. other clinical scales and questionnaires referring to OD-related mood and quality of life (other secondary endpoint), 4. gender differences in COVID-19 related OD (exploratory endpoint). Approach / methods OT will be performed twice a day with a 4-odor training set for 12 weeks. Effects of OT on COVID-19 related OD will be measured with objective and subjective efficacy variables. The sense of smell is an important function for social relationships and is therefore a challenging clinical problem with few proven therapeutic options. With this new approach, we want to investigate a possible simple treatment for an impedimental symptom of COVID-19, but also learn more about the pathomechanism of post-infectious OD. To our knowledge, this will be the first study comparing patients with COVID-19 associated OD with and without OT in clinical outcomes.

NCT ID: NCT05415254 Not yet recruiting - COVID-19 Clinical Trials

Calcitriol Supplementation in COVID-19 Patients

Start date: June 12, 2022
Phase: N/A
Study type: Interventional

This is a randomized, open label study to evaluate the efficacy and safety of calcitriol supplementation in COVID-19 patients with vitamin D deficiency.

NCT ID: NCT05413694 Not yet recruiting - COVID-19 Clinical Trials

Epidemiological Monitoring of COVID-19 Patients Hospitalized on Reunion Island

COVIDEPI-SUIV'
Start date: July 2022
Phase: N/A
Study type: Interventional

The island of Reunion, a French overseas department of 860,000 inhabitants, located in the Indian Ocean (OI) zone, recorded its first case of COVID-19 on March 11, 2020. The epidemic, which was described as not very severe during the year 2020 in Reunion was much more intense and more deadly in 2021, with the arrival of the new variants (South African and Indian) and exploded at the beginning of the year 2022 (variant Omicron). Reunion has a specific island context both climato-geographically and demographically. Indeed, this French island located in the southern hemisphere in the middle of the Indian Ocean (OI) has a tropical climate and a multi-ethnic population, younger than in mainland France (16% are over 60 years old). It is also marked by a higher prevalence in the general population of certain risk factors, such as obesity (11%) and type 2 diabetes (>10%), recognized as factors favoring severe clinical forms of COVID-19. as well as "persistent COVID-19". This study will allow the constitution of a large-scale French cohort located in a closed overseas territory to provide answers to local specificities and to the management of the epidemic in the territory.

NCT ID: NCT05408481 Not yet recruiting - COVID-19 Clinical Trials

Relation Between COVID-19 Pts and Hyponatremia in Adreno Ortical Insufficient Patients.

Start date: June 2022
Phase:
Study type: Observational

Hyponatremia in COVID-19 patients with adrenal insufficiency

NCT ID: NCT05398731 Not yet recruiting - COVID-19 Pneumonia Clinical Trials

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19

Start date: June 2022
Phase:
Study type: Observational

1. To determine the risk of COVID -19 in patients who use ACEI and ARBS 2. To determine the Effect of ACEI and ARBS on COVID -19 infection . 3. To determine the Severity of COVID -19 in patients who use ACEI and ARBS .